Related content

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly

By Dawson L.K.   Jodrell D.I.   Bowman A.   Rye R.   Byrne B.   Bernareggi A.   Camboni G.   Smyth J.F.  

European Journal of Cancer, Vol. 36, Iss. 18, 2000-12 ,pp. : 2353-2359

Elsevier

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol™), a novel isoflav-3-ene, in patients with advanced cancer

By Souza Paul   Liauw Winston   Links Matthew   Pirabhahar Saiyini   Kelly Graham   Howes Laurence  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 4, 2006-10 ,pp. : 427-433

Springer Publishing Company

Access to resources Recommend Favorite

STAT3 exon 21 mutation is rare in common human cancers

By Kim Min Sung  

Acta Oncologica, Vol. 52, Iss. 6, 2013-08 ,pp. : 1221-1222

Informa Healthcare

Access to resources Recommend Favorite

A Novel PIK3CA Hotspot Mutation in Isfahanian Breast Cancer Patients

By Gharbi Sedigheh   Faghihi Mehri   Tavassoli Manoochehr  

Cancer Investigation, Vol. 29, Iss. 4, 2011-04 ,pp. : 313-317

Informa Healthcare

Access to resources Recommend Favorite

Novel NPM1 mutation in the 3’-untranslated region identified in two patients with acute myeloid leukemia

By Abraham Ajay   Karathedath Sreeja   Kumaraswamy Vinodhini   Jayavelu Ashok Kumar   Mani Sathya   Srivastava Vivi M.   Zhang Wei   Zhou Tong   George Biju   Srivastava Alok   Mathews Vikram   Balasubramanian Poonkuzhali  

Leukemia and Lymphoma, Vol. 55, Iss. 6, 2014-06 ,pp. : 1421-1424

Informa Healthcare

Access to resources Recommend Favorite